{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}],"title":"Performance status = 0"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"Performance status = 1"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Performance status = 2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Performance status 0 = Fully active, able to carry on all pre-disease performance without restriction.\n\nPerformance status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work.\n\nPerformance status 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.","groups":[{"description":"Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.","id":"OG000","title":"Thalidomide"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and evaluable patients","reportingStatus":"POSTED","timeFrame":"baseline","title":"Initial Performance Status","type":"SECONDARY","unitOfMeasure":"Participants"}